Talphera (TLPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the stock and has a $6.00 price target.
Ed Arce has given his Buy rating due to a combination of factors that suggest a positive outlook for Talphera. The recent agreement with the FDA to reduce the enrollment target for the NEPHRO CRRT study from 166 to 70 patients is a significant development. This change is expected to expedite the study’s completion by the end of 2025, while still maintaining a strong statistical power of 90% for the primary endpoint. Additionally, the updated enrollment criteria, which now include patients on continuous renal replacement therapy for more than 48 hours and heparin-tolerant patients, are anticipated to enhance the enrollment process without affecting the study’s core objectives.
Furthermore, Talphera’s strategic plan to expand the number of clinical sites to 13 by mid-2025 is another critical factor supporting the Buy rating. The selection of new sites with high volumes of CRRT procedures and led by nephrologists is expected to address previous enrollment challenges. These sites are anticipated to significantly accelerate patient enrollment, thus advancing the NEPHRO CRRT study’s progress. Overall, these strategic updates and expansions are viewed as pivotal steps in advancing Talphera’s clinical objectives, justifying the Buy recommendation.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TLPH in relation to earlier this year.